RAC - Charts & Price Action, page-10887

another thing to note, AZ formed a collaboration in early 2020 with accent. They've just updated their website with respect to rna modification:

https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/advances-epigenetics-oncology.html

it shows they have a strong belief RNA modification, namely m6a modification, will have a broad impact in cancer. It seems accents research is continuing to be positive, and not negative.

So it's been 2 years since the collab. Chuan He has stated they won't be in the clinic for another 2-3 years. This means AZ won't know proof of concept 4-5 years *after* their initial investment at the very least, as trials take time.

Race have been open that nothing substantial will come with respect to FTO trials in terms of acquisition until after human data. We can try and rush results, but I think that will end poorly. I'd say the time to human trials should be set at the point race discovered FTO, which was 2020. I'd say we're not doing too bad.

Lets focus on where our competitors are at, to see how we are faring as a company in an emerging field.